全文获取类型
收费全文 | 24343篇 |
免费 | 2286篇 |
国内免费 | 526篇 |
专业分类
耳鼻咽喉 | 160篇 |
儿科学 | 1892篇 |
妇产科学 | 99篇 |
基础医学 | 6203篇 |
口腔科学 | 55篇 |
临床医学 | 1692篇 |
内科学 | 5483篇 |
皮肤病学 | 119篇 |
神经病学 | 349篇 |
特种医学 | 233篇 |
外科学 | 381篇 |
综合类 | 3799篇 |
现状与发展 | 4篇 |
预防医学 | 1680篇 |
眼科学 | 44篇 |
药学 | 2602篇 |
23篇 | |
中国医学 | 2034篇 |
肿瘤学 | 303篇 |
出版年
2024年 | 42篇 |
2023年 | 372篇 |
2022年 | 544篇 |
2021年 | 1018篇 |
2020年 | 979篇 |
2019年 | 939篇 |
2018年 | 810篇 |
2017年 | 948篇 |
2016年 | 1011篇 |
2015年 | 949篇 |
2014年 | 1551篇 |
2013年 | 2743篇 |
2012年 | 1464篇 |
2011年 | 1523篇 |
2010年 | 1120篇 |
2009年 | 1093篇 |
2008年 | 1049篇 |
2007年 | 1217篇 |
2006年 | 1123篇 |
2005年 | 898篇 |
2004年 | 774篇 |
2003年 | 670篇 |
2002年 | 618篇 |
2001年 | 522篇 |
2000年 | 441篇 |
1999年 | 426篇 |
1998年 | 342篇 |
1997年 | 330篇 |
1996年 | 258篇 |
1995年 | 168篇 |
1994年 | 156篇 |
1993年 | 115篇 |
1992年 | 111篇 |
1991年 | 98篇 |
1990年 | 102篇 |
1989年 | 60篇 |
1988年 | 68篇 |
1987年 | 63篇 |
1986年 | 73篇 |
1985年 | 94篇 |
1984年 | 48篇 |
1983年 | 37篇 |
1982年 | 37篇 |
1981年 | 33篇 |
1980年 | 42篇 |
1979年 | 26篇 |
1978年 | 16篇 |
1977年 | 9篇 |
1976年 | 8篇 |
1975年 | 5篇 |
排序方式: 共有10000条查询结果,搜索用时 343 毫秒
41.
Th2细胞因子调节哮喘炎症细胞转运机制的研究 总被引:1,自引:0,他引:1
目的 探讨Th2细胞因子IL-5、IL-13调节哮喘炎症过程中肺和骨髓之间的细胞转运机制。方法 建立哮喘动物模型,获取肺泡灌洗液,检测IL-5、IFN-γ,浓度并进行病理分析;应用原位杂交技术检测肺组织IL-5、IL-13 mRNA表达和骨髓IL-5mRNA表达;免疫组化法观察肺、骨髓IL-5免疫反应细胞;流式细胞仪检测骨髓CD34、CD3阳性细胞。结果 哮喘组肺泡灌洗液IL-5浓度明显高于对照组(P<0.001);哮喘组肺组织病理改变显示小气道痉挛,管壁周围炎性细胞浸润,以嗜酸粒细胞、淋巴细胞为主;哮喘组肺组织IL-5、IL-13 mRNA表达较对照组显著增加(P<0.01);哮喘组骨髓IL-5 mRNA阳性细胞明显增加(P<0.001),与肺组织IL-5 mRNA表达的增高密切相关(P<0.05);此外,哮喘组肺组织和骨髓IL-5免疫反应细胞显著增加(P<0.01),骨髓CD34、CD3细胞均显著增高(P<0.01),并且CD34增高与骨髓细胞表达IL-5 mRNA密切相关(P<0.05)。结论IL-5可能在转录和转录后水平均参与调节骨髓嗜酸粒细胞的功能和炎症细胞在肺和骨髓之间的转运。 相似文献
42.
目的 :观察氧雾化吸入备劳特和爱喘乐治疗儿童哮喘急性发作的疗效。方法 :选择 15 8例哮喘急性发作患儿作为研究对象 ,分为观察组和对照组。观察组采用氧驱动雾化吸入备劳特和爱喘乐 ;对照组静脉滴注氨茶碱和地塞米松。结果 :观察组显效率 87.3% (96 /110 ) ,总有效率 99.1% (10 9/110 ) ,临床治愈率 94 .5 % (10 4 /110 ) ;对照组显效率 2 2 .9% (11/48) ,总有效率 6 0 .4 % (2 9/48) ,临床治愈率 5 4 .2 % (2 6 /48)。观察组显效率、总有效率及临床治愈率皆显著高于对照组 ,差异有高度统计意义 (P <0 .0 1)。观察组治疗后心率较治疗前明显下降 ,差异有统计意义(P <0 .0 5 )。结论 :采用氧驱动雾化吸入备劳特和爱喘乐能快速、有效地控制哮喘发作。 相似文献
43.
Yuhei Okubo Junji Yonese Satoru Kawakami Sinya Yamamoto Yoshinobu Komai Hideki Takeshita Yuichi Ishikawa Iwao Fukui 《International journal of urology》2007,14(9):854-855
Renal cell carcinoma (RCC) causes many kinds of symptoms such as hypercalcemia, hypertension, polycythemia and fever. Here we describe a rare case of RCC presenting with a persistent cough. After radical nephrectomy, the obstinate cough disappeared. When the tumor recurred locally, the cough also recurred. Furthermore, the cough disappeared completely again after the removal of the recurrent tumor. Although all the clinical findings suggested that the RCC caused the cough, we could not identify a specific humoral substance responsible for the cough. 相似文献
44.
应用鸡卵清蛋白致敏和刺激小鼠复制过敏性气道炎症反应模型研究血小板激活因子选择性拮抗剂YM-264对抗原引起气道嗜酸性粒细胞(EOS)浸润的影响。结果发现,正常小鼠支气管肺泡灌洗液(BALF)中未见到EOS;致敏小鼠给予抗原多次反复吸入刺激后,BALF中EOS急剧增多。在YM-264治疗各组中,YM-264的不同剂量分别导致EOS数下降27.0%、48.2%及67.9%。还发现YM-264抑制EOS对气道的浸润伴随着白细胞介素(IL)-5水平的明显下降。提示YM-264通过抑制IL-5的产生从而抑制了EOS在气道的聚集。 相似文献
45.
J. Belchi-Hernandez S. Moreno-Grau F. Sánchez-Gascón J. Bayo B. Elvira Rendueles B. Bartolomé J. M. Moreno J. Martinez Quesada R. Palacios Peláez 《Allergy》1998,53(3):241-248
Zygophyllum fahago is a herbaceous plant found widely in the Mediterranean area. There are no previous reports of its allergenicity. An aerobiologic and clinical survey was conducted in Murcia, southern Spain, to determine the quantity of airborne pollen and establish the possible role of this pollen as a cause of allergic symptoms. With a Hirst volumetric trap, we determined the atmospheric concentrations of this pollen in 1993, 1994,1995, and 1996. Of 1180 patients tested, 181 (15,34%) had a positive skin test. To determine its allergenicity, we divided 47 patients into three groups: in group 1, all the patients had symptoms of rhinoconjunctivitis plus asthma; in groups 2 and 3, rhinoconjunctivitis. In group 1, we performed a bronchial provocation test (BPT): in groups 2 and 3, we performed nasal provocation (NPT) and conjunctival provocation (CPT) tests, respectively, SDS-PAGE was used to characterize the antigenic fractions and RAST inhibition to determine cross-reactivity with other pollens. The pollen dispersion period is from May to September (445 grains/m3 ), BPT was positive in 13 of 15 patients, NPT in 14 of 16 patients, and CPT in 13 of 16 patients. RAST inhibition revealed cross-reactivity with Mercurialis, Ricinus, Olea. and Betula. SDS-PAGE identified 25 IgE antibody-binding components, five of which (60, 65, 41, 38, and 15.5/14,7 kDa) were recognized by 40% of the sera. By SDS-PAGE immunoblotting with sunflower antiprofilin rabbit serum and affinity chromatography we established that the Z. fahago extract has profilin. This study shows that this pollen becomes airborne and elicits an IgE response which triggers respiratory symptoms in allergic subjects. 相似文献
46.
K. Terayama Syuji Toda Nobuhisa Yonemitsu Norimasa Koike Hajime Sugihara 《Virchows Archiv : an international journal of pathology》1997,431(4):291-295
We describe a rare case of papillary carcinoma with extensive proliferation of stromal cells. The stromal cells were immunocytochemically
positive for vimentin, α-smooth muscle actin and desmin, but negative for cytokeratin, epithelial membrane antigen, S-100,
thyroglobulin and CD34. These results and the ultrastructure of the stromal cells, which exhibited the characteristics of
both fibroblasts and smooth muscle cells, indicated an origin from myofibroblasts. We conclude that myofibroblastic proliferation
may contribute to the stromal response in the slow growth of the papillary carcinoma.
Received: 29 August 1996 / 26 May 1997 相似文献
47.
M. Ohshima A. Yokoyama H. Ohnishi H. Hamada N. Kohno J. Higaki T. Naka 《Clinical and experimental allergy》2007,37(5):735-742
BACKGROUND: Enhanced expression of the suppressor of cytokine signalling (SOCS)-5 might be of therapeutic benefit for T-helper type 2 (Th2) dominant diseases, as its expression is reported to result in a reduction of Th2 differentiation in vitro due to the inhibition of IL-4 signalling. OBJECTIVE: To investigate the regulatory role of SOCS-5 in vivo, we explored the phenotype of an experimental asthma model developed in SOCS-5 transgenic (Tg) mice. METHODS: The SOCS-5 Tg mice or wild-type (WT) mice were sensitized and repeatedly challenged with ovalbumin (OVA). We examined bronchoalveolar lavage fluid (BALF), lung specimens, and airway hyperresponsiveness (AHR) to methacholine. RESULTS: The production of IFN-gamma by CD4(+) T cells from unprimed SOCS-5 Tg mice was significantly increased in comparison with unprimed wild-type mice, indicating that SOCS-5 Tg mice have a Th1-polarizing condition under natural conditions. However, in an asthma model, significantly more eosinophils in the airways and higher levels of IL-5 and IL-13 in BALF were observed in the SOCS-5 Tg than the wild-type mice. AHR in the asthma model of SOCS-5 Tg was also more enhanced than that of wild-type mice. OVA-stimulated CD4(+) T cells from the primed SOCS-5 Tg mice produced significantly more IL-5 and IL-13 than CD4(+) T cells from wild-type mice. CONCLUSION: Our results demonstrate that the overexpression of SOCS-5 does not inhibit Th2 response, but rather augments the phenotype of the asthma model in vivo. This finding throws into question the therapeutic utility of using enhancement of SOCS-5 expression for Th2-dominant disease. 相似文献
48.
Andrea von Berg Renate Engelstätter Predrag Minic Miodrag Sréckovic Maria Luz Garcia Garcia Tadeusz Lato Jan H. Vermeulen Stefan Leichtl Stefan Hellbardt Thomas D. Bethke 《Pediatric allergy and immunology》2007,18(5):391-400
Ciclesonide is an onsite-activated inhaled corticosteroid (ICS) for the treatment of asthma. This study compared the efficacy, safety and effect on quality of life (QOL) of ciclesonide 160 microg (ex-actuator; nominal dose 200 microg) vs. budesonide 400 microg (nominal dose) in children with asthma. Six hundred and twenty-one children (aged 6-11 yr) with asthma were randomized to receive ciclesonide 160 microg (ex-actuator) once daily (via hydrofluoroalkane metered-dose inhaler and AeroChamber Plus spacer) or budesonide 400 microg once daily (via Turbohaler) both given in the evening for 12 wk. The primary efficacy end-point was change in forced expiratory volume in 1 s (FEV1). Additional measurements included change in daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events. Both ciclesonide and budesonide increased FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication after 12 wk vs. baseline. The non-inferiority of ciclesonide vs. budesonide was demonstrated for the change in FEV1 (95% confidence interval: -75, 10 ml, p = 0.0009, one-sided non-inferiority, per-protocol). In addition, ciclesonide and budesonide showed similar efficacy in improving asthma symptoms, morning PEF, use of rescue medication and QOL. Ciclesonide was superior to budesonide with regard to increases in body height (p = 0.003, two-sided). The effect on the hypothalamic-pituitary-adrenal axis was significantly different in favor of ciclesonide treatment (p < 0.001, one-sided). Both ciclesonide and budesonide were well tolerated. Ciclesonide 160 microg once daily and budesonide 400 microg once daily were effective in children with asthma. In addition, in children treated with ciclesonide there was significantly less reduction in body height and suppression of 24-h urinary cortisol excretion compared with children treated with budesonide after 12 wk. 相似文献
49.
Benjamin H. S. Lau Sharon K. Riesen Kim P. Truong Esther W. Lau Peter Rohdewald Ray A. Barreta 《The Journal of asthma》2004,41(8):825-832
A randomized, placebo-controlled, double-blind study involving 60 subjects, aged 6-18 years old, was conducted over a period of 3 months to determine the effect of Pycnogenol® (a proprietary mixture of water-soluble bioflavonoids extracted from French maritime pine) on mild-to-moderate asthma. After baseline evaluation, subjects were randomized into two groups to receive either Pycnogenol® or placebo. Subjects were instructed to record their peak expiratory flow with an Assess® Peak Flow Meter each evening. At the same time, symptoms, daily use of rescue inhalers (albuterol), and any changes in oral medications were also recorded. Urine samples were obtained from the subjects at the end of the run-in period, and at 1-, 2-, and 3-month visits. Urinary leukotriene C4/D4/E4 was measured by an enzyme immunoassay. Compared with subjects taking placebo, the group who took Pycnogenol® had significantly more improvement in pulmonary functions and asthma symptoms. The Pycnogenol® group was able to reduce or discontinue their use of rescue inhalers more often than the placebo group. There was also a significant reduction of urinary leukotrienes in the Pycnogenol® group. The results of this study demonstrate the efficacy of Pycnogenol® as an adjunct in the management of mild-to-moderate childhood asthma. 相似文献
50.
Xiao-Mei Mai Per-Olof Gäddlin Lennart Nilsson Ingemar Leijon 《Pediatric allergy and immunology》2005,16(5):380-385
Early catch-up growth and subsequent overweight are suggested to be associated with later cardiovascular diseases and later type II diabetes. However, the impact of early catch-up growth and childhood overweight on the development of asthma has been less studied, particularly in children born with very low birth weight (VLBW). A birth cohort of 74 VLBW children (birth weight < or = 1500 g) was followed from birth and investigated on asthma at 12 yr of age. Early rapid weight gain was in one way defined as an increase of weight > or =1 standard deviation score (SDS) at 6 months of corrected postnatal age. Current overweight was defined by body mass index (BMI) exceeding 21.2 and 21.7 kg/m(2), respectively, for boys and girls at 12 yr of age. Current asthma was diagnosed by a pediatrician, according to asthma ever in combination with a positive response to hypertonic saline bronchial provocation test and/or wheeze at physical examination at 12 yr old. Being overweight at 12 yr of age was associated with an increased risk for current asthma in the VLBW children [crude odds ratio (OR): 5.5, 95% confidence interval (CI): 1.3-22.2]. After adjustment for early weight gain and neonatal risk, the OR of overweight increased nearly three times (adjusted OR: 15.3, 95% CI: 2.5-90.6). Early rapid weight gain seemed to be inversely associated with current asthma (adjusted OR: 0.49 for an increase of weight equal to 1 SDS, 95% CI: 0.23-1.02, p = 0.06). In addition, early rapid weight gain was inversely associated with the magnitude of bronchial responsiveness at 12 yr (coefficient -1.15, p < 0.01). There was a strong and positive association between overweight and asthma at 12 yr of age in the VLBW children. This strong association had been reduced by early rapid weight gain, possibly via the reduction of bronchial responsiveness. 相似文献